

NOV 26 2004

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of
-------	---	----

Complete if Known

Application Number	10/825,643
Filing Date	4/15/2004
First Named Inventor	Mohammad R. Marzabadi
Art Unit	4614 1624
Examiner Name	Not Yet Known
Attorney Docket Number	62524-AA

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
DR		WO 00/06565 A1	02-10-2000			
DR		WO 00/25770 A1	05-11-2000			
DR		WO 98/33791 A1	08-06-1998			
DR		WO 98/19998 A2	05-14-1998			
DR		WO 98/03494 A1	01-29-1998			

Examiner Signature	/Deepak Rao/	Date Considered	06/22/2006
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/825,643
Filing Date	4/15/2004
First Named Inventor	Mohammad R. Marzabadi
Art Unit	1614 1624
Examiner Name	Not Yet Known
Attorney Docket Number	62524-AA

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code* Number * Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
DR		WO 96/14846 A1	05-23-1996			
DR		EP 0 921 125 B1	06-09-1999			
DR		EP 0 444 546 B1	09-04-1991			

Examiner
Signature

/Deepak Rao/

Date

Considered

06/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/825,643
				Filing Date	4/15/2004
				First Named Inventor	Mohammad R. Marzabadi
				Art Unit	4614 1624
				Examiner Name	Not Yet Known
Sheet	3	of	3	Attorney Docket Number	62524-AA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DR		FONTENLA, J.A. et al., Journal of Medicinal Chemistry. (1994) 37(16): 2564-2573	<input type="checkbox"/>
DR		MURALI DHAR, T.G. et al., Journal of Medicinal Chemistry. (1999) 42(23): 4778-4793	<input type="checkbox"/>
DR		NISHIKAWA, T. et al., Arzneimittel Forschung/Drug Research. (1996) 46(Part II), (No. 9): 875-878	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature	/Deepak Rao/	Date Considered	06/22/2006
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
62524-AA/JPW/MJWU.S. Serial No.
Not Yet KnownApplicants:
Mohammad R. Marzabadi, et al.

10/825,643

Filing Date:
Herewith 4/15/04Group Art Unit:
1624INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
DR	4 4 3 8 1 1 7	3/20/84	Cherkofsky et al.			
DR	4 6 8 4 6 5 5	8/4/87	Atwal, et al.			
DR	4 6 8 4 6 5 6	8/4/87	Atwal, et al.			
DR	4 6 8 4 6 5 3	8/4/87	Taylor, E.C., et al			
DR	4 7 0 3 1 2 0	10/27/87	Press, et al.			
DR	4 7 2 8 6 5 2	3/1/88	Atwal, et al.			
DR	4 8 4 5 2 1 6	7/4/89	Taylor, E.C., et al			
DR	4 8 5 5 3 0 1	8/8/89	Atwal et al.			
DR	4 8 8 2 3 3 4	11/21/89	Shih, et al.			
DR	4 9 0 2 7 9 6	2/20/90	Taylor et al.			
DR	4 9 4 6 8 4 6	8/7/90	Nomura et al.			
DR	5 1 3 4 1 4 5	7/28/92	Brouwer, et al.			
DR	5 1 4 9 8 1 0	9/22/92	Perrior, et al.			
DR	5 2 0 2 3 3 0	4/13/93	Atwal, et al.			
DR	5 2 5 0 5 3 1	10/5/93	Cooper, et al.			
DR	5 2 9 2 7 4 0	3/8/94	Burri, et al.			
DR	5 5 2 1 1 8 9	5/28/96	Boykin, et al.			
DR	5 5 4 1 1 8 6	7/30/96	Breu, et al.			
DR	5 5 0 0 4 2 4	3/19/96	Nagamine, et al.			
DR	5 5 9 4 1 4 1	1/14/97	Yuan, et al.			
DR	5 9 4 2 5 1 7	8/24/99	Nagarathnam, et al.			
DR	6 0 3 7 3 5 4	3/14/00	Patane et al.			
DR	6 2 4 5 7 7 3	6/12/01	Wong et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
DR	9 2 0 0 7 4 1	1/23/92	PCT				
DR	9 2 1 4 4 5 3	9/3/92	PCT				
DR	9 4 1 0 9 8 9	5/26/94	PCT				
DR	9 4 2 2 8 2 9	10/13/94	PCT				

EXAMINER /Deepak Rao/

DATE CONSIDERED

06/22/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicants: Mohammad R. Marzabadi, et al.
 Serial No.: Not Yet Known
 Filed: Herewith
 For: Selective Melanin Concentrating Hormone-
 I (MCH1) Receptor Antagonists And Uses
 Thereof Exhibit A

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
62524-AA/JPW/MJWU.S. Serial No.
~~Not Yet Known~~INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)Applicants:
Mohammad R. Marzabadi, et al.

10/825,643

Filing Date:
Herewith 4/15/04Group Art Unit:
1624

FOREIGN PATENT DOCUMENTS

		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No
DR		9	7	4	2	9	5	6	11/20/97	PCT				
DR		9	8	5	1	3	1	1	11/19/98	PCT				
DR		9	9	0	7	6	9	5	2/18/99	PCT				
DR		9	9	4	8	5	3	0	9/30/99	PCT				
DR			1	6	2	2	0	8	11/27/85	EPO				
DR			2	0	4	3	1	7	12/10/86	EPO				
DR			2	3	4	8	3	0	9/2/87	EPO				
DR			2	3	6	9	0	2	9/16/87	EPO				
DR			2	3	7	3	4	7	9/16/87	EPO				
DR			2	8	0	2	2	7	8/31/88	EPO				
DR			4	0	0	6	6	5	12/5/90	EPO				
DR			4	5	9	6	6	6	12/4/91	EPO				
DR			6	2	2	3	6	9	11/2/94	EPO				
DR			6	2	2	3	6	6	11/2/94	EPO				
DR			6	2	7	4	2	7	12/7/94	EPO				
DR		2	6	1	0	6	2	5	8/12/88	French				
DR		5	6	5	9	7	7	8	5/23/81	Japanese				
DR	6	1	2	8	2	3	6	7	12/12/86	Japanese				
DR		6	2	8	7	5	7	4	4/22/87	Japanese				
DR	6	2	2	6	5	2	7	1	11/18/87	Japanese				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DR		U.S. Serial No. 09/899,635, filed July 5, 2001, Lagu, et al;
DR		Atwal, K.S. et al., "Synthesis of Substituted 1,2,3,4- Tetrahydro-6- Methyl-2-Thioxo-5-Pyrimidinecarboxylic Acid Esters," Heterocycles (1987) 26(5): 1189-1192;
DR		Atwal, K. S. et al., "Substituted 1,4-Dihydropyrimidines. 3. Synthesis of Selectively Functionalized 2-Hetero-1,4-dihyropyrimidines," Journal of Organic Chemistry (1989) 54: 5898-5907;
EXAMINER /Deepak Rao/		DATE CONSIDERED 06/22/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 62524-AA/JPW/MJW	U.S. Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Mohammad R. Marzabadi, et al.	
				Filing Date: Herewith 4/15/04	Group Art Unit: 1624
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
DR		Atwal, K. S. et al., Dihydropyrimidines Calcium Channel Blockers: 2-Heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," <i>Journal of Medicinal Chemistry</i> (1990) 33(5): 1510-1515;			
DR		Atwal, K.S. et al., "Dihydropyrimidines Calcium Channel Blockers. 2. 3-Substituted-4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic Acid Esters as Potent Mimics of Dihydropyridines," <i>Journal of Medicinal Chemistry</i> (1990) 33(9):2629-2635;			
DR		Atwal, K. S. et al., "Dihydropyrimidine Calcium Channel Blockers. 3. 3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidenecarboxylic Acid Esters as Orally Effective Antihypertensive Agents," <i>Journal of Medicinal Chemistry</i> (1991) 34(2) : 806-811;			
DR		Barrio, et al., "A Direct Method For Preparation of 2-Hydroxyethoxymethyl Derivatives of Guanine, Adenine, and Cytosine," <i>Journal of Medicinal Chemistry</i> (1980) 23(5):572-574;			
DR		Boer, R., et al., "(+)-Niguldipine binds with very high affinity to Ca ²⁺ channels and to a subtype of α_1 -adrenoceptors," <i>European Journal of Pharmacology - Molecular Pharmacology Section</i> (1989) 172: 131-145;			
DR		Brown, et al., "Inhibitors of Bacillus subtilis DNA Polymerase III. 6-(Arylalkylamino)uracils and 6-Anilino-uracils," <i>Journal of Medicinal Chemistry</i> (1997) 20(9): 1186-1189;			
DR		Cho H., Takeuchi Y., Ueda M., and Mizuno A. Regioselective synthesis of N-substituted dihydropyrimidine-2 (1-H) or (3H)-One. <i>Tetrahedron Letters</i> , Vol. 29 (42) : 5405-5408, 1988;			
DR		Cho, H. et al., "Dihydropyrimidines: Novel Calcium Antagonists with Potent and Long-Lasting Vasodilative and Antihypertensive Activity," <i>Journal of Medicinal Chemistry</i> (1989) 32: 2399-2406;			
DR		D'Eletto, R. D. and Javitt, N.B., "Effect of Doxazosin on Cholesterol Synthesis In Cell Culture," <i>Journal of Cardiovascular Pharmacology</i> (1989) 13, Supp. 2: S1-S4;			
DR		Forray et al., "The α_1 -Adrenergic Receptor That Mediates Smooth Muscle Contraction in Human Prostate Has The Pharmacological Properties of the Cloned Human α_{1c} Subtype," <i>Molecular Pharmacology</i> (1994) 45: 703-708;			
DR		Khanina, E. L. et al., Alkylation of derivatives of 2-oxo-4-phenyl-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid. <i>Chemical Abstracts</i> 89: 43319 (1978);			
DR		Mamaev, V.P. and Dubovenko, Z.D., Pyrimidines. XXI. 5-Substituted 2-hydroxy-4,6-diphenylpyrimidines. <i>Chemical Abstracts</i> 73: 77187 (1970);			
EXAMINER /Deepak Rao/		DATE CONSIDERED 06/22/2006			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 62524-AA/JPW/MJW	U.S. Serial No. Not Yet Known
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicants: Mohammad R. Marzabadi, et al.	
				Filing Date: Herewith 4/15/04	Group Art Unit: 1624
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
DR		McGrath, J. C. et al., "Alpha-Adrenoceptors: A Critical Review," <i>Medicinal Research Reviews</i> (1989) 9(4): 407-553;			
DR		Rovnyak, G. C. et al., "Dihydropyrimidine Calcium Channel Blockers. 4. Basic 3-Substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic Acid Esters. Potent Antihypertensive Agents," <i>Journal of Medicinal Chemistry</i> (1992) 35(17): 3254-3263;			
DR		Spiers, J. P. et al., "UK-52,046 (A Novel α_1 -Adrenoceptor Antagonist) and the Role of α -Adrenoceptor Stimulation and Blockade on Atrioventricular Conduction," <i>Journal of Cardiovascular Pharmacology</i> (1990) 16(5): 824-830;			
DR		Triggle, D. J., "Dihydropyrimidine Calcium Channel Blockers. 2.3-Substituted 4-Aryl-1, 4-dihydro-6-methyl-5-pyrimidine-Carboxylic Acid Esters as Potent Mimics of Dihydropyridines," <i>Chemtracts-Organic Chemistry</i> (Jan./Feb. 1991) 68-72;			
DR		Wetzel, J. M., et al., "Discovery of α_{1A} -Adrenergic Receptor Antagonists Based on the L-Type Ca^{2+} Channel Antagonist Niguldipine" <i>Journal of Medicinal Chemistry</i> (1995) 38(10): 1579-1581; and			
DR		Zhan, G. L. et al., "Bunazosin Reduces Intraocular Pressure By Increasing Uveoscleral Outflow In Rabbits," <i>Investigative Ophthalmology and Visual Science</i> (1993) 34(4): Abst. No. 1133-49, p. 928.			
EXAMINER	DATE CONSIDERED				
/Deepak Rao/	06/22/2006				
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					